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ABSTRACT 
Amikacinis a semisynthetic derivative of Kanamycin; it was approved for clinical use in the U.S. in 1976. Amikacin is broad-
spectrum and potent aminoglycoside with limited clinical use owing high dose requirement.Many gram-negative bacteria, including 
many strains of Pseudomonas, Enterobacter, and serratiaare inhibited by 1-20 mcg/ml amikacin in vitro. After injection of 500mg of 
amikacin every 12hours (15mg/kg/d) intramuscularly, peak levels in serum are 10-30 mcg/ml. Amikacinis valuable because it was 
more active to aminoglycoside inactivating bacterial enzymes than is gentamicin. Since it was more inflated, amikacin was reserved 
for treatment of infections with gentamicin-resistant organisms. Peak plasma concentration should be kept between 20-30 mg/ml and 
trough concentration below 10mg/ml.There is no oral form of Amikacinis available as it is not absorbed orally. Various research on 
oral formulation of amikacinare going onsuch assignificantly improved oral uptake of amikacin in fvb mice in the presence of crl-
1605 copolymer, liposomal amikacin dry powder inhaler effect of fines on in vitro performance, thiolated chitosan nanoparticles as 
an oral delivery system for amikacin. 
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1. INTRODUCTION 
1.1. Improvement of oral uptake of amikacin in mice 
This research was going oral uptake of amikacin 
improved by crl-1605 copolymer because amikacin is a 
highly polar molecule and is insoluble in lipid at 
physiological pH it exists as polycations. Amikacin 
drugs can’t be given orally because it cannot absorb 
from the intestine. However intramuscular injection of 
amikacin rapidly absorbed and its peak plasma 
concentration is observed usually immediately after 30 
min. and intravenous administration produces peak 
plasma concentration after infusion. The common 
phenotype is mediated by the presence of a membrane 
located pump, P-glycoprotein which facilitates the 
energy dependent transport of drugs out of the cell 
1,2
. 
The P-glycoprotein is related to a family of transport 
proteins, ATP-binding cassette transporters 
3,4
. Oral 
absorption of some drugs is also inhibited by P- 
glycoprotein pumps on brush border of intestinal 
mucosa. Therefore, P-glycoprotein inhibitors may have 
potential to transport drug through gut, which is 
otherwise poorly absorbed after oral administration. 
Nonionic block copolymers synthesized from ethylene 
oxide and propylene oxide were developed specifically 
for use as surfactants. Because the sizes and relative 
positions of hydrophilic poly-oxy-ethylene and poly-
oxy-propylene blocks can be altered during synthesis, 
copolymers with significantly different surfactant 
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characteristics can be produced. The CRL polymer 
containing 9000-20,000 Daltons poly-oxy-propylene 
(POP) cores flanked by poly-oxy-ethylene (POE) blocks 
that make up 2.52 % of the total molecular weight. The 
high molecular weight CRL copolymer like (XL-1605 is 
soluble in aqueous buffer at concentrations up to 70 
mg/ml at temperature below 8
0
C. The temperature 
increases through the cloud point, the copolymer 
molecules aggregate into uniformly sized but complex 
detergent micro-particles or micelles in which the 
hydrophobic POP portion of each molecule is positioned 
internally and the hydrophilic POE components exposed 
to the external aqueous environment. Because (XL-1605 
can inhibit P-glycoprotein pump, It was observed the 
possibility of delivering amikacin orally in mice using 
CRL 1605 copolymer as a vehicle. To Chinnaswamy 
Jagannath knowledge, this was the first report of 
significantly improved uptake of amikacin when 
delivered orally in an animal or human model. 
1.2. Liposomal inhaler of amikacin: effect of fines on 
in vitro performance 
Amikacin sulfate is a broad-spectrum and potent 
aminoglycoside with limited clinical use owing to a high 
dose requirement and renal and audio-vestibular 
apparatus toxicity 
5, 6
. The major drawbacks associated 
with the use of earlier or conventional liposomal 
formulations are the tendency of liposomes to leak drug 
while in circulation, the extensive uptake of these 
liposomes by tissues of reticula endothelial systems 
(RES), and the inability of liposomes to extravagate into 
infected tissue 
7, 8
. Therefore, localized liposomal 
amikacin delivery was considered for the treatment of 
cystic fibrosis infections in the lungs. Liposomal 
encapsulation of Amikacin will give the required release 
of drug for longer time duration at the localized site, 
thereby reducing both the chances of systemic side 
effects and the frequency of dosing 
9.
 
1.3. In vitro and ex vivo evaluations of amikacin oral 
delivery system 
The pharmaceutical research focus was being steadily 
shifted from the development of new chemical entities to 
the development of novel drug delivery systems (NDDS) 
of existing drug molecules to maximize their 
effectiveness in terms of therapeutic action. Effective 
slow-release and permeation enhancing regimens have 
demonstrated superior patient compliance 
10
.Thiolated 
polymers (Thiomers) are mucoadhesive polymers which 
displaythiol group bearing side chains. The backbone 
consists of safe polymers such as Chitosan that modify 
the release pattern of drugs. The interest is growing to 
develop mucoadhesive DDS that will attach to a tissue 
or to the surface coating of the tissue for the targeting of 
various absorptive mucosa. A biodegradable polymer 
such as Chitosan, a naturally polycationic 
biocompatible, biodegradable and non-toxic copolymer, 
was an established mucoadhesive and absorption 
enhancing polymer 
11
. Chitosan exhibits poor solubility 
at pH values above 6 that prevents enhancing effects at 
sites of absorption of drugs 
12
. Thiomers exhibit 
mucoadhesive, permeation enhancing, controlled release 
as well as enzyme and efflux pump inhibitory and tight 
junctions opening properties. These features make the 
Thiomer technology highly interesting for non-invasive 
drug delivery routes. In the presence of 0.5% thiolated 
polycarbophil, for instance, the apparent permeability 
coefficient of insulin could be improved 
13
. Thiomers 
can be directly given compressed to tablets or given as 
solutions 
14
. The potential of applications of such 
mucoadhesive polymers for the delivery of small organic 
molecules, proteins, vaccines and DNA are already 
discus about it but still experiments regarding the 
delivery of antibiotics such as Amikacin using Thiomers 
use as drug delivery vehicles are lacking. Oral drug 
delivery to accomplish intracellular effects of such high-
molecular weight hydrophilic agents needs to be coupled 
with the use of an absorption-enhancing agent, which is 
safe and biodegradable. Colloidal drug carriers such as 
liposomes and nanoparticles are easily taken up by 
phagocytic cells and accumulate in the organs of the 
reticula endothelial system (RES). Therefore, they hold 
promise as carriers for many different drugs including 
antibiotics used for the treatment of intracellular 
infections that would not normally find easy access into 
intracellular sites. Amikacin was a polycationic 
aminoglycoside. Aminoglycosides are water-soluble 
weak bases that were polycations at body pH. 
Aminoglycosides cannot be delivered orally probably 
due to the efflux by P-glycoprotein pumps in the brush 
border of intestine and their high solubility in water 
15
. 
More recently Werle and Hoffer revealed efflux pum 
inhibitory capability of Thiomers 
16
. The thiol groups on 
Thiomers can be, to some extent, oxidized under mild 
conditions to form intermolecular covalent bonds, and as 
a result, modulate water absorption and swelling 
behavior of nanoparticles to improve drug delivery and 
release 
17
.It was trying to demonstrate that amikacin 
could be loaded in thiolated nanoparticles to increase its 
absorption from intestinal tract by increasing the 
mucoadhesion of the particles and facilitating 
nanoparticle uptake by cells.These particles later on 
could also be utilize as vehicles to deliver amikacin by 
tracheal routes against obligate aerobes such as 
Mycobacterium Tuberculosis. 
2. DISCUSSION 
2.1. Improvement of oral uptake of amikacin in mice 
It was observed a good correlation between the target 
amikacin concentration and observed concentration of 
amikacin in normal mouse serum supplemented with 
known amount of amikacin. Therefore, the fluorescence 
polarization immunoassay for amikacin which is 
intended for monitoring concentrations of amikacin in 
human serum can also be used to measure the 
concentration of amikacin in sera of mice. Inexperiments 
take separate series to fed mice with CRL 1605 and 
collected blood after 1 h and 2 h. Sera were separated 
from blood cells by centrifugation. Sera were 
supplemented with known concentration of amikacin. 
The target concentration of amikacinwas 8.0 µg/ml. In 
the serum containing CRL -1605 and collected 1 h after 
gavage, the observed concentration of amikacin was 
7.7µg/ml. Similarly, the serum collected after 2 h of 
gavage and then supplemented in vitro with amikacin, 
the observed concentration of Amikacin was 7.9 µg/ml. 
Again, the target concentration of amikacin was 8.0 
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µg/ml. Therefore, we conclude that CRL 1605 has no 
effect in the fluorescence polarization immunoassay of 
amikacin. In the first set of experiments to estimated 
serum concentration of amikacin at a 1 hour interval. In 
this experiment, it was not only demonstrated 
significantly elevated serum amikacin level in mice in 
the presence of CRL1605, but also demonstrated none 
detected amikaoin levels when vehicle control or CRL 
1605 copolymer were used for gavage. In this 
experiment mice divided four group and used three mice 
in each group. This experiment also established that the 
higher concentration of amikacin in mice receiving 
amikacin along with the copolymer CRL 1605 was due 
to improved gastrointestinal absorption and not due to 
cross reactivity of CRL -1605 with the arnikacin 
antibody in the amikacin immune assay. In separate sets 
of experiments, there was used five mice in each groups. 
The first group was control where mice received 
amikacin alone. The second group of mice received 
amikacin along with the copolymer GRL 1605. It was 
observed significantly elevated concentrations of 
arnikacin in the second group of mice compared to the 
first group (controls), indicating that oral uptake of 
amikacin was increased significantly in the presence of 
CRL-1605, In experiments one through and five used 
relatively high dose of amikacin and observed 
significantly improved oral uptake of amikacin in the 
presence of copolymer CRL-1605. Interestingly when 
we used lower dose of amikacin (100 mg/Kg) in 
experiment 6, and again observed significantly improved 
oral uptake of amikacin in the presence of CRL 1605. 
Therefore, accomplish that in both doses, CRL-1605 is 
effective in delivering amikacin orally in mice. These 
preliminary experiments indicate a potential for 
delivering amikacin orally in man using CRL-1600 
copolymer as a vehicle. Other aminoglycosides may also 
be delivered using this approach because all 
aminoglycosides are polar and exist as polycations at 
physiological PH. Therefore, other aminoglycosides can 
also be incorporated into CIU-1605 vehicle. In 
assumption, it was demonstrated that the oral uptake of 
amikacin is significantly improved in the presence of 
copolymer CRL-1605. Because amikacin was a 
relatively inexpensive drug and CRL-1605 is nontoxic 
(unpublished data, available on request from cytRx 
Corporation), it was possible to use large dose of 
amikacin in oral formulation. However, mice and human 
may behave differently in the uptake of amikacin in the 
presence of the copolymer. Our goal is study 
structurallyrelated polymers such as CRL 1072 in order 
to investigate which polymer produces best oral uptake 
of amikacin concentrations in sera of mice in the 
presence and absence of CRL 1605 Amikacin will also 
consider the possibility of delivering other 
aminoglycosides, for exampletobramycin orally using 
CRL 1605 and other structurally related copolymers. 
2.2. Liposomal inhaler of amikacin: effect of fines on 
in vitro performance 
The liposomal amikacin were prepared using modified 
reverse phase evaporation (REV) technique using 
alternative organic solvents such as ethyl acetate and 
ethanol (1:1). The organic solvents such as methanol or 
diethyl ether employed in the liposome preparation 
(although usually removed by evaporation) may remain 
as traces in the final formulation and can lead to a 
possible risk for human health and inadequate stability 
of the vesicles 
18.
 Use of other organic solvents such as 
ethanol and ethyl acetate can solve this problem. Ethanol 
forms a monophasic system upon contact with aqueous 
phase, while ethyl acetate forms a biphasic system 
(emulsion) upon contact with aqueous phase. When 
ethyl acetate was used alone, it resulted in distorted 
spherical vesicles, which may be due to formation of an 
unstable biphasic system upon contact with the aqueous 
phase. Use of ethanol alone resulted in high   percentage 
drug entrapment (PDE), which may be due to formation 
of a monophasic system upon contact with the aqueous 
phase. However, drug leakage was observed due to the 
presence of traces of ethanol leading to disruption of the 
bilayer. In the case of ethyl acetate: ethanol (1:1) 
combination, proper spherical vesicles and high PDE 
were observed. Combination of these organic solvents 
with aqueous phase forms a stable emulsion, which is a 
prerequisite for REV 
19
. When the aqueous phase to 
organic phase ratio was raised from 1:3 to 1:5, marked 
increase in the PDE was observed. Further increase in 
the organic phase did not result in increase in PDE. The 
prepared liposomes were found to be multilamellar and 
were identified by the presence of Maltese crosses in 
liposomes. The prepared liposomes were extruded by 
passing through 2μm polycarbonate membranes to a 
reproducible mean liposomal size below 5μm 20.The 
liposomal dispersion was dialyzed and free drug was 
removed. PDE in liposomes was 96.7 ± 1.9 and 98.5 ± 
1.4 for AMK1 and AMK2, respectively. Laser light 
scattering microscopy revealed mean liposomal sizes for 
AMK1 and for AMK2. Difference in liposomal size may 
be due to the presence of a different charge present on 
the liposomal surface. The prepared liposomes were 
lyophilized using appropriate optimized and 
cryoprotectant for the drug retained in lyophilized 
liposomal amikacin as described previously 
21
. 
Liposomes were best preserved in their structure with 
PDR using sucrose as a cryoprotectant in mass ratio of 
lipid:sucrose at 1:4. During the freeze-drying process of 
liposomes, liposomes constrict and get coated on the 
optimum surface of crystallized sugar. Hydration of 
polar head groups with the hydroxyl group of sucrose 
leads to stabilization of liposomes. If the concentration 
of sucrose was less than optimum, the crystallized sugar 
does not provide adequate surface for the adherence of 
the constricted bilayer leading to drug leakage. Hence, it 
may be concluded that the bulk concentration of sugar 
required as cryoprotectant depends on the type of sugar 
selected and saturation of the polar head groups of the 
bilayer by drug or other formulation components. The 
lamellarity and size of liposomes were expected to 
change these requirements. To formulate AMK LDPI 
formulation, a series of experiments was conducted. 
Lyophilized liposomes when formulated as an LDPI 
formulation without using any carrier molecule resulted 
in low FPF value. This observation describes the 
importance of the addition of lactose carrier in 
formulating the LDPI formulation. Pharmatose 325M 
was sieved to get 63- to 90-μm size range fraction as a 
carrier to formulate LDPI formulations. The lyophilized 
liposomes were mixed with sieved Pharmatose 325M  in 
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the range of liposome: lactose mass ratio from 1:1 to 1:6, 
and Pharmatose 325M’s effect on FPF was studied The 
data revealed the optimum liposome: lactose mass ratio 
of 1:5. Optimum concentration of carrier is required to 
achieve detachment of liposomal drug from carrier 
molecule. Carrier concentration of less or more than 
optimum resulted in low FPF or no further increase in 
FPF. The effects of fines  in 5%, 10%, and 15% 
proportion (wt/wt) and mixing sequence with carrier and 
sieved lyophilized liposomes keeping the final liposome: 
lactose mass ratio of 1:5 were evaluated. Data revealed 
an optimum concentration of 10% wt/wt fines (sieved 
Sorbolac 400) and mixing sequence of fines with carrier 
and then with sieved lyophilized liposomes. At the 10% 
level of fines, high-energy adhesion sites (HA) of lactose 
may bind strongly to the carrier and low-energy 
adhesion sites (LA) may allow the formation of more 
reversible bonds with liposomal drug. This action results 
in efficient detachment of liposomal drug from the 
carrier as observed with plain DPI formulations 
22
 
Hence, 10% sieved Sorbolac 400 (wt/wt) added to AMK 
LDPI formulation.  
The EI of AMK2 was found to be better than the AMK1, 
suggesting more effective liposomal drug deposition into 
lung. This finding may be due to turbo-electrification or 
charge generation in liposomal powder during dispersion 
via the Rotahaler. The lower ratio of EI/FPF is 
suggestive of efficient dispersion of AMK1 from the 
device, but unlike the control more proportion of the 
dispersed powder has been deposited in the upper 
respiratory tract  
24
. Evaluation and control of flow and 
dispersion or deaggregation characteristics of the 
formulation are of critical importance in the 
development of DPI products. Interparticle forces that 
influence flow and dispersion properties are particularly 
dominant in micronized or microcrystalline powders 
required for inhalation therapy 
25,26
. It has been 
demonstrated that powder adhesion, mediated in part by 
Van der Waal forces, is directly related to particles 
27.
 
2.3. In vitro and ex vivo evaluations of amikacin oral 
delivery system 
2.3.1. Synthesis of chitosan conjugates 
LMW Chitosan (15 KDa) soluble at pH 7 was prepared. 
LMW Chitosan when formulated yields smaller and 
more uniform particles 
28
 The carboxylic acid moieties 
of NAC and NAP were activated applying EDAC [1-
ethyl-3-(3-
dimethylaminopropyl)carbodiimide].Chitosan-Cysteine 
conjugate was synthesized the same way as a control to 
compare with new thiomers (NAC, NAP conjugates). 
Chitosan was also prepared as control exactly following 
the same procedure as described but omitting EDAC 
during the coupling reaction. The lyophilized NAC 
Chitosan and NAP Chitosan appeared as odorless, white 
powders of fibrous structure. They easily swell in pH 
values below 7 and forma transparent gel of high 
viscosity. The lyophilized conjugates should be stored in 
cool temperature at 4
0
C.FTIR analyses were conducted 
to demonstrate the success of the synthesis process. 
2.3.2. Determination of the thiol group content 
The thiol group content of the polymers was determined 
using iodometric method. The highest coupling rate was 
achieved at the polymer to NAP or NAC ratio of 1:1. 
Results showed that the amount of covalently bound 
groups could not increase by raising the share of NAP or 
NAC during the coupling reaction. When increasing the 
amount of EDAC added to activate the carboxylic 
moieties of the polymer augmented the amount of thiol 
groups immobilized on the polymer chain (Fig.1) 
 
 
Figure 1: The influence of the amount of edac added on the amount of thiol groups 
 
Another parameter affecting the thiol groups 
conjugation to Chitosan was the pH value of the reaction 
medium. Figure 4 shows results from conjugation of 
polymers in different pH values. It appears that setting 
the pH of the medium at 5 leads to higher amounts of 
thiol groups on the polymer in comparison to thiol 
groups obtained at lower or higher pH values. A pH 
value of 3.5 gives lower amounts of covalently attached 
thiol groups. At this pH-value, EDAC could not gain its 
full reactive potential. At a pH-value of 5 the yield of 
polymer-bound of thiol groups is highest, as EDAC has 
gained full potential, but as the pH-value increases, 
oxidation of sulfhydryl groups during the coupling 
reaction was too increase, producing fewer polymer 
bound thiol groups. 
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Figure 2: The influence of ph value on the amount of thiol groups immobilized on polymer 
 
2.3.3. Disintegration studies-Results achieved of 
disintegration studies show that Thiomer tablets 
(polymers synthesized in a pH value of 5) were more 
soluble in acetate buffer compared to Chitosan tablets. 
This observation could be attributed to the presence of 
thiol and acetyl groups on the polymers and the use of 
LMW Chitosan which all contribute to higher polymer 
solubility in water. 
2.3.4. Drug permeation studies 
The results in vitro permeation studies were carried out 
using rat gut. The viability of the tissue was determined 
measuring the concentration of glucose.As glucose is 
actively transported, inside concentration the sac was 
higher than in the incubation solution and tissue 
viability could be maintained for up to 150 min. shows 
that an acceptable amount of permeation in over 2 hrs 
was achieved. According to the results 82% of the 
entrapped amikacin permeated through the rat gut 
membrane.
 
 
Figure 3: Time versus concentration of amikacin released from 2grof nap-chitosan-amikacin nanoparticles 
 
2.3.5. Tensile studies 
The results achieved by tensile studies demonstrate a 6 
fold increase in mucoadhesion of NAC-Chitosan and a 7 
fold increase in mucoadhesion of NAP-Chitosan 
compared to Chitosan control tablets. According to the 
results above experiments achieved NAP-Chitosan 
shows our desired properties and is the chosen polymer 
for future experiments. 
 
 
Figure 4: Twa results for thiomer and chitosan tablets 
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CONCLUSION 
Amikacinis a semisynthetic derivative of Kanamycin; it 
was approved for clinical use in the U.S. in 1976. 
Amikacin is broad-spectrum and potent aminoglycoside 
with limited clinical use owing high dose 
requirement.Many gram-negative bacteria, including 
many strains of Pseudomonas, Enterobacter, and serratia 
are inhibited by 1-20 mcg/ml amikacin in vitro. in this 
article discussed about the oral uptake of Amikacin By 
three different formulation.inhance the oral uptake. 
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